<SEC-DOCUMENT>0001144204-16-101431.txt : 20160513
<SEC-HEADER>0001144204-16-101431.hdr.sgml : 20160513
<ACCEPTANCE-DATETIME>20160513080058
ACCESSION NUMBER:		0001144204-16-101431
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160513
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160513
DATE AS OF CHANGE:		20160513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STAAR SURGICAL CO
		CENTRAL INDEX KEY:			0000718937
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		IRS NUMBER:				953797439
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1228

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-11634
		FILM NUMBER:		161645915

	BUSINESS ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		6263037902

	MAIL ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STAAR SURGICAL COMPANY
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v439867_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">WASHINGTON, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Section&nbsp;13 or 15(d) of
the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date of Report (Date of Earliest Event Reported):</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 13, 2016</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 18pt">STAAR Surgical
Company</FONT><BR>
<FONT STYLE="font-size: 10pt">__________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-decoration: underline; text-align: center; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Delaware</U></FONT></TD>
    <TD STYLE="text-decoration: underline; text-align: center; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>0-11634</U></FONT></TD>
    <TD STYLE="text-decoration: underline; text-align: center; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>95-3797439</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">File Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification No.)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-decoration: underline; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>1911 Walker Ave, Monrovia, California</U></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-decoration: underline; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>91016</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&rsquo;s telephone number, including area code:</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">626-303-7902</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Not Applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">______________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Former name or former address, if changed
since last report</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.3pt 0pt 4.5pt; text-align: justify">Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.4pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.4pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><B>Item 7.01 Regulation FD Disclosure. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.25in">STAAR
Surgical Company issued a press release regarding the approval of its EVO Visian ICL, STAAR&rsquo;s Implantable Collamer<SUP>&reg;</SUP>
Lens, for distribution in Canada by the Medical Devices Bureau of Health Canada. A copy of the press release is furnished as Exhibit
99.1 to this Report, and is incorporated herein by this reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information furnished herewith pursuant to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed to be
&ldquo;filed&rdquo; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;),
or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report shall not be incorporated
by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the
date of this Current Report, regardless of any general incorporation language in the filing</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 9.01</B></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Financial Statements and Exhibits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-decoration: underline; font-size: 10pt; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit No.</U></B></FONT></TD>
    <TD STYLE="text-decoration: underline; font-size: 10pt; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Description</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;99.1</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated May 13, 2016.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt">Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">STAAR Surgical Company&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 13, 2016</FONT></TD>
    <TD STYLE="width: 5%; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 45%; text-decoration: underline; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>/s/ Caren Mason</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Caren Mason</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v439867_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 50.25pt; width: 248.25pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><B>STAAR Surgical Announces Approval
By Health Canada of Its EVO Visian ICL&trade; for Surgeons and Their Patients in Canada</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>MONROVIA, CA, May 13, 2016</B>---STAAR
Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems
for the eye, was notified yesterday of the approval of its EVO Visian ICL, STAAR&rsquo;s Implantable Collamer<SUP>&reg;</SUP> Lens,
for distribution in Canada by the Medical Devices Bureau of Health Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">With extensive clinical experience
globally, the EVO ICL is STAAR&rsquo;s next-generation lens implanted in the eye that works with the patient&rsquo;s natural eye
to correct vision. Unlike traditional contact lenses that are placed on the surface of the eye, the EVO ICL is positioned inside
the eye between the iris and the natural lens where it stays indefinitely.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We are very pleased with Health Canada&rsquo;s approval
that allows us to offer the EVO ICL for myopia, with a broad power range of -3.0 to -18.0 diopters, to our surgeons and their patients
in Canada. This represents an important new treatment option for eligible patients between 21 and 45 years old living with nearsightedness.
This approval reinforces our deep commitment to patients seeking visual freedom, as we continue to build our growing EVO ICL portfolio.
STAAR looks forward to bringing this visual freedom choice to the Canadian refractive surgery market,&rdquo; said Caren Mason,
President and CEO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The EVO ICL has an extensive clinical history of safety and
effectiveness, as was recently reinforced at the&nbsp;American Society of Cataract and Refractive Surgery (ASCRS) Meeting earlier
this month in New Orleans, Louisiana, as part of the Evolution of Visual Freedom&trade; initiative. The EVO ICL, with its central
hole, offers premium refractive outcomes with efficiency and comfort for both the patient and the surgeon by eliminating the extra
surgical step of the peripheral iridotomy. Approximately 200,000 lenses from the EVO ICL product family have been implanted globally
to date. Clinical data show that the EVO ICL provides outstanding, predictable correction of high degrees of refractive errors,
with the vast majority of patients achieving and maintaining 20/20 or better visual acuity through five years of follow up.<SUP>1</SUP>
Review of the peer-reviewed published literature demonstrates an excellent safety profile: specifically, eight studies including
data from 1,291 eyes followed for up to five years describe a zero incidence of significant complications.<SUP>2</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About STAAR Surgical</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">STAAR, which has been dedicated solely to ophthalmic surgery
for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems.
These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses.
All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR&rsquo;s lens used in
refractive surgery is called an Implantable Collamer&reg; Lens or &ldquo;ICL&rdquo;. Nearly 600,000 Visian ICLs have been implanted
to date. To learn more about the ICL go to: www.visianinfo.com. STAAR has approximately 360 employees and markets lenses in over
60 countries. Headquartered in Monrovia, CA, the company operates manufacturing facilities in Aliso Viejo, CA and Monrovia, CA.
For more information, please visit the Company&rsquo;s website at www.staar.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Safe Harbor</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All statements in this press release that are not statements
of historical fact are forward-looking statements, including statements about any of the following: statements regarding products
and their safety or efficacy, or potential future sales in Canada or elsewhere, and any statements of assumptions underlying any
of the foregoing. Important factors that could cause actual results to differ materially from those indicated by such forward-looking
statements are set forth in the Company&rsquo;s Annual Report on Form 10-K for the year ended January 1, 2016, under the caption
&ldquo;Risk Factors&rdquo;, which is on file with the Securities and Exchange Commission and available in the &ldquo;Investor Information&rdquo;
section of the company&rsquo;s website under the heading &ldquo;SEC Filings.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These statements are based on expectations and assumptions as
of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ
materially from those described in the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>Shimizu K, Kamiya K, Igarashi A, Kobashi H. Long-Term Comparison of Posterior Chamber Phakic Intraocular Lens With and Without
a Central Hole (Hole ICL and Conventional ICL) Implantation for Moderate to High Myopia and Myopic Astigmatism. Medicine. 2016
Apr;95(14):e3270.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Packer M. Meta-Analysis and Review: Effectiveness, Safety and Central Port Design of the Intraocular Collamer Lens (ICL). In
press.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONTACT:</FONT></TD>
    <TD STYLE="width: 34%; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investors</B></FONT></TD>
    <TD STYLE="width: 33%; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Media</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EVC Group</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EVC Group</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian Moore, 310-579-6199</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dave Schemelia, 646-445-4800</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Doug Sherk, 415-652-9100</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 40&3 P$1  (1 0,1 ?_$ +4  0 !! ,  P
M       ) 0<("@(%!@,$"P$!  ,  P$!              $" P0&!P4($
M!@(" 0,"! $'!@\    ! @,$!08 !Q$("2$2$S$402(5"E%A<9&Q,B06\(%"
M([87H<%B5"5UM38G=QB(.7DZ$0 " 0(% @,& @@%!0       0(1 R$Q$@0%
M009180?P<8$B,A.AP9&Q0E)B<B,4T>&"%0@S0R0T%O_:  P# 0 "$0,1 #\
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MZI^3+BE4*< $H_V@Y#T^H<\9QDFZTZ'U=2IC@WT>#_1F<\@D8!03 'IZC_,
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M] X'53<%]J9Q Q3 (\:8KZLC*3M91J;(1?4I?Y0#^K(2JZ&3/SP?(EYD._\
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MQ@R=G>G.[IS06X+!56R3*LW=W%"Y"'N,>Q;%391[J3!@Y3<HH%31$Z!52)I
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M;+GX(DJ8##Z!QD_%>WP*/3TJ3/Y5^61 P!@# & , 8!\9DBF'D>>?;[>>?\
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M50 <8(2H,$E.,5(<4RN"5@4XR:D:45R"1@# :J4 .,$)4*B'. U4 '&"4J#
M& , 8 P!@ 0YP0U4IP'\O].34C2O,J <9!9*@P!@# & , 8 P!@%!#G!#297
M!*5,!@# & , ?7 :J #C!"5!@D8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
E@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@'__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
